Reirradiation for recurrent craniopharyngioma

Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in radiation oncology 2020-11, Vol.5 (6), p.1305-1310
Hauptverfasser: Foran, Sarah J., Laperriere, Normand, Edelstein, Kim, Janzen, Laura, Tadic, Tony, Ramaswamy, Vijay, Shultz, David, Gentili, Fred, Bouffet, Eric, Tsang, Derek S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1310
container_issue 6
container_start_page 1305
container_title Advances in radiation oncology
container_volume 5
creator Foran, Sarah J.
Laperriere, Normand
Edelstein, Kim
Janzen, Laura
Tadic, Tony
Ramaswamy, Vijay
Shultz, David
Gentili, Fred
Bouffet, Eric
Tsang, Derek S.
description Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy. A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed. We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment. Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients.
doi_str_mv 10.1016/j.adro.2020.07.020
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7718531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2452109420302116</els_id><sourcerecordid>2483406625</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-667bc77e920a0d468287fa367eca22652420a5df7b31f3ae2748f76f85e9a4fc3</originalsourceid><addsrcrecordid>eNp9kE1LAzEYhIMottT-AQ_So5dd850tiCDFLygIoueQZt-0Ke2mJrsF_70prVIvnibwzkyGB6FLgkuCibxZlqaOoaSY4hKrMssJ6lMuaEHwmJ8evXtomNIS45xiijB8jnqMMSzwmPZR8QY-RlN70_rQjFyIowi2ixGadmSjaXzYLEz8auY-rM0FOnNmlWB40AH6eHx4nzwX09enl8n9tLBciLaQUs2sUjCm2OCay4pWyhkmFVhDqRSU54OonZox4pgBqnjllHSVgLHhzrIButv3brrZGmqbx0Sz0pvo13mLDsbrv5fGL_Q8bLVSpBKM5ILrQ0EMnx2kVq99srBamQZClzTlFeNYSiqyle6tNoaUIrjfbwjWO9R6qXeo9Q61xkpnyaGr44G_kR-w2XC7N0DGtPUQdbIeGgu1z3xbXQf_X_83siKQCA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2483406625</pqid></control><display><type>article</type><title>Reirradiation for recurrent craniopharyngioma</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Foran, Sarah J. ; Laperriere, Normand ; Edelstein, Kim ; Janzen, Laura ; Tadic, Tony ; Ramaswamy, Vijay ; Shultz, David ; Gentili, Fred ; Bouffet, Eric ; Tsang, Derek S.</creator><creatorcontrib>Foran, Sarah J. ; Laperriere, Normand ; Edelstein, Kim ; Janzen, Laura ; Tadic, Tony ; Ramaswamy, Vijay ; Shultz, David ; Gentili, Fred ; Bouffet, Eric ; Tsang, Derek S.</creatorcontrib><description>Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy. A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed. We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment. Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients.</description><identifier>ISSN: 2452-1094</identifier><identifier>EISSN: 2452-1094</identifier><identifier>DOI: 10.1016/j.adro.2020.07.020</identifier><identifier>PMID: 33305092</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Scientific</subject><ispartof>Advances in radiation oncology, 2020-11, Vol.5 (6), p.1305-1310</ispartof><rights>2020 The Authors</rights><rights>2020 The Authors.</rights><rights>2020 The Authors 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-667bc77e920a0d468287fa367eca22652420a5df7b31f3ae2748f76f85e9a4fc3</citedby><cites>FETCH-LOGICAL-c455t-667bc77e920a0d468287fa367eca22652420a5df7b31f3ae2748f76f85e9a4fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718531/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718531/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33305092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Foran, Sarah J.</creatorcontrib><creatorcontrib>Laperriere, Normand</creatorcontrib><creatorcontrib>Edelstein, Kim</creatorcontrib><creatorcontrib>Janzen, Laura</creatorcontrib><creatorcontrib>Tadic, Tony</creatorcontrib><creatorcontrib>Ramaswamy, Vijay</creatorcontrib><creatorcontrib>Shultz, David</creatorcontrib><creatorcontrib>Gentili, Fred</creatorcontrib><creatorcontrib>Bouffet, Eric</creatorcontrib><creatorcontrib>Tsang, Derek S.</creatorcontrib><title>Reirradiation for recurrent craniopharyngioma</title><title>Advances in radiation oncology</title><addtitle>Adv Radiat Oncol</addtitle><description>Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy. A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed. We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment. Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients.</description><subject>Scientific</subject><issn>2452-1094</issn><issn>2452-1094</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEYhIMottT-AQ_So5dd850tiCDFLygIoueQZt-0Ke2mJrsF_70prVIvnibwzkyGB6FLgkuCibxZlqaOoaSY4hKrMssJ6lMuaEHwmJ8evXtomNIS45xiijB8jnqMMSzwmPZR8QY-RlN70_rQjFyIowi2ixGadmSjaXzYLEz8auY-rM0FOnNmlWB40AH6eHx4nzwX09enl8n9tLBciLaQUs2sUjCm2OCay4pWyhkmFVhDqRSU54OonZox4pgBqnjllHSVgLHhzrIButv3brrZGmqbx0Sz0pvo13mLDsbrv5fGL_Q8bLVSpBKM5ILrQ0EMnx2kVq99srBamQZClzTlFeNYSiqyle6tNoaUIrjfbwjWO9R6qXeo9Q61xkpnyaGr44G_kR-w2XC7N0DGtPUQdbIeGgu1z3xbXQf_X_83siKQCA</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Foran, Sarah J.</creator><creator>Laperriere, Normand</creator><creator>Edelstein, Kim</creator><creator>Janzen, Laura</creator><creator>Tadic, Tony</creator><creator>Ramaswamy, Vijay</creator><creator>Shultz, David</creator><creator>Gentili, Fred</creator><creator>Bouffet, Eric</creator><creator>Tsang, Derek S.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201101</creationdate><title>Reirradiation for recurrent craniopharyngioma</title><author>Foran, Sarah J. ; Laperriere, Normand ; Edelstein, Kim ; Janzen, Laura ; Tadic, Tony ; Ramaswamy, Vijay ; Shultz, David ; Gentili, Fred ; Bouffet, Eric ; Tsang, Derek S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-667bc77e920a0d468287fa367eca22652420a5df7b31f3ae2748f76f85e9a4fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Scientific</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Foran, Sarah J.</creatorcontrib><creatorcontrib>Laperriere, Normand</creatorcontrib><creatorcontrib>Edelstein, Kim</creatorcontrib><creatorcontrib>Janzen, Laura</creatorcontrib><creatorcontrib>Tadic, Tony</creatorcontrib><creatorcontrib>Ramaswamy, Vijay</creatorcontrib><creatorcontrib>Shultz, David</creatorcontrib><creatorcontrib>Gentili, Fred</creatorcontrib><creatorcontrib>Bouffet, Eric</creatorcontrib><creatorcontrib>Tsang, Derek S.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advances in radiation oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Foran, Sarah J.</au><au>Laperriere, Normand</au><au>Edelstein, Kim</au><au>Janzen, Laura</au><au>Tadic, Tony</au><au>Ramaswamy, Vijay</au><au>Shultz, David</au><au>Gentili, Fred</au><au>Bouffet, Eric</au><au>Tsang, Derek S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reirradiation for recurrent craniopharyngioma</atitle><jtitle>Advances in radiation oncology</jtitle><addtitle>Adv Radiat Oncol</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>5</volume><issue>6</issue><spage>1305</spage><epage>1310</epage><pages>1305-1310</pages><issn>2452-1094</issn><eissn>2452-1094</eissn><abstract>Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy. A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed. We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment. Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33305092</pmid><doi>10.1016/j.adro.2020.07.020</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2452-1094
ispartof Advances in radiation oncology, 2020-11, Vol.5 (6), p.1305-1310
issn 2452-1094
2452-1094
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7718531
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Scientific
title Reirradiation for recurrent craniopharyngioma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A59%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reirradiation%20for%20recurrent%20craniopharyngioma&rft.jtitle=Advances%20in%20radiation%20oncology&rft.au=Foran,%20Sarah%20J.&rft.date=2020-11-01&rft.volume=5&rft.issue=6&rft.spage=1305&rft.epage=1310&rft.pages=1305-1310&rft.issn=2452-1094&rft.eissn=2452-1094&rft_id=info:doi/10.1016/j.adro.2020.07.020&rft_dat=%3Cproquest_pubme%3E2483406625%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2483406625&rft_id=info:pmid/33305092&rft_els_id=S2452109420302116&rfr_iscdi=true